Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism

Veronica De Rosa, Francesca Di Rella, Antonio Di Giacomo, Giuseppe Matarese

Research output: Contribution to journalArticle

Abstract

Novel concepts in immunometabolism support the hypothesis that glucose consumption is also used to modulate anti-tumor immune responses, favoring growth and expansion of specific cellular subsets defined in the past as suppressor T cells and currently reborn as regulatory T (Treg) cells. During the 1920s, Otto Warburg and colleagues observed that tumors consumed high amounts of glucose compared to normal tissues, even in the presence of oxygen and completely functioning mitochondria. However, the role of the Warburg Effect is still not completely understood, particularly in the context of an ongoing anti-tumor immune response. Current experimental evidence suggests that tumor-derived metabolic restrictions can drive T cell hyporesponsiveness and immune tolerance. For example, several glycolytic enzymes, deregulated in cancer, contribute to tumor progression independently from their canonical metabolic activity. Indeed, they can control apoptosis, gene expression and activation of specific intracellular pathways, thus suggesting a direct link between metabolic switches and pro-tumorigenic transcriptional programs. Focus of this review is to define the specific metabolic pathways controlling Treg cell immunobiology in the context of anti-tumor immunity and tumor progression.

Original languageEnglish
JournalCytokine and Growth Factor Reviews
DOIs
Publication statusPublished - Jun 2017

Fingerprint

T-cells
Regulatory T-Lymphocytes
Metabolism
Tumors
Immunity
Neoplasms
Glucose
Mitochondria
T-Lymphocytes
Immune Tolerance
Gene expression
Metabolic Networks and Pathways
Transcriptional Activation
Chemical activation
Switches
Tissue
Apoptosis
Oxygen
Gene Expression
Enzymes

Keywords

  • Concomitant immunity
  • Glycolysis
  • Metabolism
  • Treg
  • Tumor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Endocrinology, Diabetes and Metabolism
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Regulatory T cells as suppressors of anti-tumor immunity : Role of metabolism. / De Rosa, Veronica; Di Rella, Francesca; Di Giacomo, Antonio; Matarese, Giuseppe.

In: Cytokine and Growth Factor Reviews, 06.2017.

Research output: Contribution to journalArticle

@article{ae4213b05a674b38a9f6c4de5e54e2b6,
title = "Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism",
abstract = "Novel concepts in immunometabolism support the hypothesis that glucose consumption is also used to modulate anti-tumor immune responses, favoring growth and expansion of specific cellular subsets defined in the past as suppressor T cells and currently reborn as regulatory T (Treg) cells. During the 1920s, Otto Warburg and colleagues observed that tumors consumed high amounts of glucose compared to normal tissues, even in the presence of oxygen and completely functioning mitochondria. However, the role of the Warburg Effect is still not completely understood, particularly in the context of an ongoing anti-tumor immune response. Current experimental evidence suggests that tumor-derived metabolic restrictions can drive T cell hyporesponsiveness and immune tolerance. For example, several glycolytic enzymes, deregulated in cancer, contribute to tumor progression independently from their canonical metabolic activity. Indeed, they can control apoptosis, gene expression and activation of specific intracellular pathways, thus suggesting a direct link between metabolic switches and pro-tumorigenic transcriptional programs. Focus of this review is to define the specific metabolic pathways controlling Treg cell immunobiology in the context of anti-tumor immunity and tumor progression.",
keywords = "Concomitant immunity, Glycolysis, Metabolism, Treg, Tumor",
author = "{De Rosa}, Veronica and {Di Rella}, Francesca and {Di Giacomo}, Antonio and Giuseppe Matarese",
year = "2017",
month = "6",
doi = "10.1016/j.cytogfr.2017.04.001",
language = "English",
journal = "Cytokine and Growth Factor Reviews",
issn = "1359-6101",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Regulatory T cells as suppressors of anti-tumor immunity

T2 - Role of metabolism

AU - De Rosa, Veronica

AU - Di Rella, Francesca

AU - Di Giacomo, Antonio

AU - Matarese, Giuseppe

PY - 2017/6

Y1 - 2017/6

N2 - Novel concepts in immunometabolism support the hypothesis that glucose consumption is also used to modulate anti-tumor immune responses, favoring growth and expansion of specific cellular subsets defined in the past as suppressor T cells and currently reborn as regulatory T (Treg) cells. During the 1920s, Otto Warburg and colleagues observed that tumors consumed high amounts of glucose compared to normal tissues, even in the presence of oxygen and completely functioning mitochondria. However, the role of the Warburg Effect is still not completely understood, particularly in the context of an ongoing anti-tumor immune response. Current experimental evidence suggests that tumor-derived metabolic restrictions can drive T cell hyporesponsiveness and immune tolerance. For example, several glycolytic enzymes, deregulated in cancer, contribute to tumor progression independently from their canonical metabolic activity. Indeed, they can control apoptosis, gene expression and activation of specific intracellular pathways, thus suggesting a direct link between metabolic switches and pro-tumorigenic transcriptional programs. Focus of this review is to define the specific metabolic pathways controlling Treg cell immunobiology in the context of anti-tumor immunity and tumor progression.

AB - Novel concepts in immunometabolism support the hypothesis that glucose consumption is also used to modulate anti-tumor immune responses, favoring growth and expansion of specific cellular subsets defined in the past as suppressor T cells and currently reborn as regulatory T (Treg) cells. During the 1920s, Otto Warburg and colleagues observed that tumors consumed high amounts of glucose compared to normal tissues, even in the presence of oxygen and completely functioning mitochondria. However, the role of the Warburg Effect is still not completely understood, particularly in the context of an ongoing anti-tumor immune response. Current experimental evidence suggests that tumor-derived metabolic restrictions can drive T cell hyporesponsiveness and immune tolerance. For example, several glycolytic enzymes, deregulated in cancer, contribute to tumor progression independently from their canonical metabolic activity. Indeed, they can control apoptosis, gene expression and activation of specific intracellular pathways, thus suggesting a direct link between metabolic switches and pro-tumorigenic transcriptional programs. Focus of this review is to define the specific metabolic pathways controlling Treg cell immunobiology in the context of anti-tumor immunity and tumor progression.

KW - Concomitant immunity

KW - Glycolysis

KW - Metabolism

KW - Treg

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=85017808871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017808871&partnerID=8YFLogxK

U2 - 10.1016/j.cytogfr.2017.04.001

DO - 10.1016/j.cytogfr.2017.04.001

M3 - Article

JO - Cytokine and Growth Factor Reviews

JF - Cytokine and Growth Factor Reviews

SN - 1359-6101

ER -